Healthcare provider profile · identity verified

Mary Mccarty, M.D.

Internal Medicine · WEST CHESTER, OH · NPI 1255657417

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	732	197
Levothyroxine Sodium	Levothyroxine Sodium	401	94
Amlodipine Besylate	Amlodipine Besylate	353	83
Lisinopril	Lisinopril	325	77
Losartan Potassium	Losartan Potassium	318	79
Omeprazole	Omeprazole	249	53
Metformin Hcl	Metformin Hcl	171	48
Pantoprazole Sodium	Pantoprazole Sodium	161	36
Hydrochlorothiazide	Hydrochlorothiazide	155	38
Metformin Hcl Er	Metformin Hcl	144	37
Escitalopram Oxalate	Escitalopram Oxalate	136	31
Carvedilol	Carvedilol	105	24
Bupropion Xl	Bupropion Hcl	100	18
Rosuvastatin Calcium	Rosuvastatin Calcium	99	31
Metoprolol Tartrate	Metoprolol Tartrate	95	25
Gabapentin	Gabapentin	93	29
Trazodone Hcl	Trazodone Hcl	92	28
Eliquis	Apixaban	88	20
Sertraline Hcl	Sertraline Hcl	87	26
Alendronate Sodium	Alendronate Sodium	86	24
Jardiance	Empagliflozin	83	17
Fluoxetine Hcl	Fluoxetine Hcl	81	16
Tamsulosin Hcl	Tamsulosin Hcl	79	23
Metoprolol Succinate	Metoprolol Succinate	78	23
Duloxetine Hcl	Duloxetine Hcl	74	17
Januvia	Sitagliptin Phosphate	62	13
Montelukast Sodium	Montelukast Sodium	62	13
Furosemide	Furosemide	61	21
Simvastatin	Simvastatin	60	15
Citalopram Hbr	Citalopram Hydrobromide	56	15
Lovastatin	Lovastatin	56	15
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	54	17
Pravastatin Sodium	Pravastatin Sodium	53	15
Glipizide Er	Glipizide	51	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	51	11
Meloxicam	Meloxicam	51	17
Ozempic	Semaglutide	51	13
Allopurinol	Allopurinol	50	14
Potassium Chloride	Potassium Chloride	49	16
Albuterol Sulfate Hfa	Albuterol Sulfate	48	26
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	47	12
Atenolol	Atenolol	46	12
Rybelsus	Semaglutide	42	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	41	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	40	34
Famotidine	Famotidine	39	suppressed
Prednisone	Prednisone	39	28
Celecoxib	Celecoxib	36	suppressed
Lorazepam	Lorazepam	36	suppressed
Clopidogrel	Clopidogrel Bisulfate	35	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	35	12
Xarelto	Rivaroxaban	35	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	34	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	33	suppressed
Trulicity	Dulaglutide	33	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	32	28
Tramadol Hcl	Tramadol Hcl	32	suppressed
Ezetimibe	Ezetimibe	31	suppressed
Buspirone Hcl	Buspirone Hcl	29	suppressed
Synthroid	Levothyroxine Sodium	29	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	28	12
Clonazepam	Clonazepam	27	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	27	suppressed
Levetiracetam	Levetiracetam	27	suppressed
Mirtazapine	Mirtazapine	27	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	27	14
Clonidine Hcl	Clonidine Hcl	25	suppressed
Propranolol Hcl Er	Propranolol Hcl	25	suppressed
Donepezil Hcl	Donepezil Hcl	24	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	24	suppressed
Fluticasone Propionate	Fluticasone Propionate	24	12
Spironolactone	Spironolactone	24	suppressed
Warfarin Sodium	Warfarin Sodium	23	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Azithromycin	Azithromycin	22	16
Finasteride	Finasteride	22	suppressed
Tizanidine Hcl	Tizanidine Hcl	22	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	22	suppressed
Cephalexin	Cephalexin	21	16
Fenofibrate	Fenofibrate	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	20	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	20	20
Benazepril Hcl	Benazepril Hcl	19	suppressed
Diazepam	Diazepam	19	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	19	suppressed
Farxiga	Dapagliflozin Propanediol	16	suppressed
Incruse Ellipta	Umeclidinium Bromide	16	suppressed
Naproxen	Naproxen	16	12
Nystatin	Nystatin	16	suppressed
Solifenacin Succinate	Solifenacin Succinate	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Valsartan	Valsartan	16	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	15	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	12
Sucralfate	Sucralfate	15	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Fluconazole	Fluconazole	14	13
Glipizide	Glipizide	14	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Lidocaine	Lidocaine	13	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	13	suppressed
Pen Needle	Pen Needle, Diabetic	13	suppressed
Verapamil Er	Verapamil Hcl	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	11
Glimepiride	Glimepiride	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Klor-Con M20	Potassium Chloride	12	suppressed
Movantik	Naloxegol Oxalate	12	suppressed
Pregabalin	Pregabalin	12	suppressed
Ramipril	Ramipril	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	11	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	11	suppressed
Methylprednisolone	Methylprednisolone	11	suppressed
Novolog Flexpen	Insulin Aspart	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error